$OTLK
Outlook Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022013086 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.998M $5.775M $6.690M
YoY Change 42.77% 97.11% 63.17%
% of Gross Profit
Research & Development $8.990M $11.25M $12.22M
YoY Change -9.51% 31.64% 43.27%
% of Gross Profit
Depreciation & Amortization $51.47K $40.91K $40.91K
YoY Change 1.58% 0.0% 0.0%
% of Gross Profit
Operating Expenses $13.99M $11.25M $12.22M
YoY Change 4.11% -1.97% 43.27%
Operating Profit -$17.02M -$18.91M
YoY Change 48.36% 49.78%
Interest Expense -$367.0K -$368.8K -$424.4K
YoY Change -406.27% -46.73% 69.75%
% of Operating Profit
Other Income/Expense, Net $11.00K -$147.3K -$368.6K
YoY Change -112.41% 402.05% 60.26%
Pretax Income -$14.34M -$17.54M -$19.70M
YoY Change 7.01% 43.81% 50.35%
Income Tax $1.000K $2.000K
% Of Pretax Income
Net Earnings -$14.35M -$17.54M -$19.70M
YoY Change 7.02% 43.81% 50.34%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08 -$0.09
Diluted Earnings Per Share -$64.91K -$0.08 -$0.09
COMMON SHARES
Basic Shares Outstanding 226.1M 220.5M 219.1M
Diluted Shares Outstanding 220.5M 219.1M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.40M $26.02M $58.42M
YoY Change 20.17% 32.14% 57.18%
Cash & Equivalents $17.40M $26.02M $58.42M
Short-Term Investments
Other Short-Term Assets $10.12M $11.49M $8.123M
YoY Change 43.99% -5.84% 22.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $27.52M $37.51M $66.55M
YoY Change 27.95% 17.61% 51.97%
LONG-TERM ASSETS
Property, Plant & Equipment $70.36K $40.91K $81.81K
YoY Change -57.0% -80.0% -67.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $804.9K $812.2K $824.0K
YoY Change -5.71% 74.79% -8.45%
Other Assets $132.0K $140.4K $141.9K
YoY Change -24.39% -27.78% -86.74%
Total Long-Term Assets $1.007M $1.074M $1.139M
YoY Change -22.71% 9.1% -13.72%
TOTAL ASSETS
Total Short-Term Assets $27.52M $37.51M $66.55M
Total Long-Term Assets $1.007M $1.074M $1.139M
Total Assets $28.53M $38.59M $67.69M
YoY Change 25.06% 17.35% 50.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.491M $2.481M $4.160M
YoY Change 58.97% -7.14% -34.28%
Accrued Expenses $3.428M $3.581M $2.550M
YoY Change 98.64% 2.54% -43.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.93M $10.47M $22.80M
YoY Change 1074.09% -9.53% 103.39%
Total Short-Term Liabilities $19.73M $18.43M $31.41M
YoY Change 192.2% -6.15% 31.43%
LONG-TERM LIABILITIES
Long-Term Debt $4.270K $7.350K $10.33K
YoY Change -99.96% -66.13% -93.54%
Other Long-Term Liabilities $57.14K $68.32K $302.0K
YoY Change -89.61% -85.54% -24.51%
Total Long-Term Liabilities $61.41K $75.67K $312.3K
YoY Change -99.46% -84.69% -44.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.73M $18.43M $31.41M
Total Long-Term Liabilities $61.41K $75.67K $312.3K
Total Liabilities $19.79M $18.51M $31.72M
YoY Change 8.72% -8.08% 29.7%
SHAREHOLDERS EQUITY
Retained Earnings -$408.9M -$394.6M -$377.1M
YoY Change 19.25% 19.76%
Common Stock $417.7M $414.7M $413.0M
YoY Change 20.2% 21.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.737M $20.08M $35.96M
YoY Change
Total Liabilities & Shareholders Equity $28.53M $38.59M $67.69M
YoY Change 25.06% 17.35% 50.05%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$14.35M -$17.54M -$19.70M
YoY Change 7.02% 43.81% 50.34%
Depreciation, Depletion And Amortization $51.47K $40.91K $40.91K
YoY Change 1.58% 0.0% 0.0%
Cash From Operating Activities -$10.25M -$21.10M -$14.33M
YoY Change 14.02% 4.49% 21.99%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.626M -11.30M 2.608M
YoY Change -56.93% -515.69% -93.98%
NET CHANGE
Cash From Operating Activities -10.25M -21.10M -14.33M
Cash From Investing Activities
Cash From Financing Activities 1.626M -11.30M 2.608M
Net Change In Cash -8.625M -32.40M -11.73M
YoY Change 65.39% 85.43% -137.12%
FREE CASH FLOW
Cash From Operating Activities -$10.25M -$21.10M -$14.33M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
225942719
dei Entity Central Index Key
EntityCentralIndexKey
0001649989
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
176461628
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37759
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
16018
dei Entity Registrant Name
EntityRegistrantName
OUTLOOK THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3982704
dei Entity Address Address Line1
EntityAddressAddressLine1
485 Route 1 South
dei Entity Address Address Line2
EntityAddressAddressLine2
Building F, Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Iselin
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08830
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
619-3990
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OTLK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
226144634
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26021429
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14477324
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11491956
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7030823
CY2022Q2 us-gaap Assets Current
AssetsCurrent
37513385
CY2021Q3 us-gaap Assets Current
AssetsCurrent
21508147
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40906
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163625
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
80924
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
111429
CY2022Q2 us-gaap Equity Method Investments
EquityMethodInvestments
812156
CY2021Q3 us-gaap Equity Method Investments
EquityMethodInvestments
853660
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140356
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
174590
CY2022Q2 us-gaap Assets
Assets
38587727
CY2021Q3 us-gaap Assets
Assets
22811451
CY2022Q2 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
10459372
CY2021Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
904200
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
14354
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
26464
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38203
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
42854
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2480871
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2196349
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3580535
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1725721
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18429964
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6752217
CY2021Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
10885854
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
7349
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26995
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
68319
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51705239
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
29332
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-454599
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
363476
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17539961
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12196547
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
522918
CY2022Q2 us-gaap Liabilities
Liabilities
18505632
CY2021Q3 us-gaap Liabilities
Liabilities
18204002
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7300000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7300000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
325000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
325000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
225942719
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
176461628
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
2259427
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1764616
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
412413161
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345726087
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394590493
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-342883254
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20082095
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4607449
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38587727
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22811451
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11249191
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8545279
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33341333
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29023253
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5774769
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2929717
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15741888
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9267962
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17023960
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11474996
us-gaap Operating Income Loss
OperatingIncomeLoss
-49083221
us-gaap Operating Income Loss
OperatingIncomeLoss
-38291215
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-11805
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-435346
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-41504
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-435346
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-356947
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-256873
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1126808
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-666945
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1025402
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-376963
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-882903
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-229714
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39756982
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17539961
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12196547
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-51707239
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39758982
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
220497826
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
168420675
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
209108090
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146860652
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4607449
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17750
CY2021Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57456903
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1204048
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-14462729
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48823421
CY2022Q1 otlk Stock Issue During Period Value In Connection With Exercise Of Warrants
StockIssueDuringPeriodValueInConnectionWithExerciseOfWarrants
188100
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2892914
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3762795
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-19704549
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
35962681
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
291501
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1367874
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17539961
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20082095
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2826291
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1154641
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-14455914
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-10474982
CY2021Q1 otlk Stock Issue During Period Value In Connection With Exercise Of Warrants
StockIssueDuringPeriodValueInConnectionWithExerciseOfWarrants
3585809
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
39517119
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1129747
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13106521
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
20651172
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3096227
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1198384
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12196547
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
12749236
us-gaap Net Income Loss
NetIncomeLoss
-51707239
us-gaap Net Income Loss
NetIncomeLoss
-39758982
us-gaap Depreciation And Amortization
DepreciationAndAmortization
153224
us-gaap Depreciation And Amortization
DepreciationAndAmortization
211466
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1025402
us-gaap Paid In Kind Interest
PaidInKindInterest
1199697
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
52291
us-gaap Paid In Kind Interest
PaidInKindInterest
640215
us-gaap Share Based Compensation
ShareBasedCompensation
6334717
us-gaap Share Based Compensation
ShareBasedCompensation
3482772
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-882903
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-454599
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
363476
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
552340
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-41504
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-435346
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4461133
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6904417
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-298523
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-31646
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-140272
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
284522
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
194029
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
308776
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3532940
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46423872
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45263124
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60675552
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42514237
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
8032
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
188100
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3585809
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17750
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
20779
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
23098
us-gaap Repayments Of Debt
RepaymentsOfDebt
12292646
us-gaap Repayments Of Debt
RepaymentsOfDebt
3649743
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
600000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57967977
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52419173
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11544105
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7156049
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14477324
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12535986
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26021429
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19692035
us-gaap Interest Paid Net
InterestPaidNet
1556088
us-gaap Interest Paid Net
InterestPaidNet
17915
otlk Amortization Of Deferred Offering Cost
AmortizationOfDeferredOfferingCost
34234
otlk Amortization Of Deferred Offering Cost
AmortizationOfDeferredOfferingCost
82654
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146860652
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.     Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outlook Therapeutics, Inc. (“Outlook” or the “Company”) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to “Outlook Therapeutics, Inc.” in November 2018. The Company is a pre-commercial biopharmaceutical company focused on developing and commercializing ONS-5010, an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has been actively monitoring the ongoing COVID-19 pandemic and its impact globally. Given the Company’s current infrastructure needs and current strategy, the Company was able to transition to remote working with limited impact on productivity as shelter-in-place and similar government orders were imposed. All development activities are currently active in support of the Company’s Biologics License Application (“BLA”) registration program for ONS-5010 for wet age-related macular degeneration (“wet AMD”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition will depend on future developments that are highly uncertain, including any new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. Management believes the financial results for the nine months ended June 30, 2022 were not significantly impacted by COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394590493
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, including as a result of the ongoing COVID-19 pandemic, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</p>
CY2022Q2 us-gaap Notes And Loans Payable
NotesAndLoansPayable
10459372
CY2021Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
11790054
CY2022Q2 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
10459372
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17539961
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12196547
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-51707239
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39758982
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
220497826
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168420675
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
209108090
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2021Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
904200
CY2021Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
10885854
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
11217
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1067351
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1067351
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1026445
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
903726
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40906
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163625
CY2021Q2 us-gaap Depreciation
Depreciation
40906
CY2022Q2 us-gaap Depreciation
Depreciation
40906
us-gaap Depreciation
Depreciation
122719
us-gaap Depreciation
Depreciation
122718
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
8413
us-gaap Operating Lease Cost
OperatingLeaseCost
33650
us-gaap Operating Lease Cost
OperatingLeaseCost
95663
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1324246
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
753808
CY2022Q2 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1455024
CY2021Q3 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
808780
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
12909
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
586649
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
214616
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
150224
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3580535
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1725721
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10847966
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
11842345
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
388594
otlk Finance Lease Cost
FinanceLeaseCost
2547
otlk Finance Lease Cost
FinanceLeaseCost
3997
CY2020Q3 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3000000
CY2021Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
625000
CY2022Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
750000
CY2022Q2 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
723
CY2021Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1210
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2547
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3997
CY2022Q2 otlk Finance Lease Cost
FinanceLeaseCost
723
CY2021Q2 otlk Finance Lease Cost
FinanceLeaseCost
1210
CY2022Q2 us-gaap Lease Cost
LeaseCost
11940
CY2021Q2 us-gaap Lease Cost
LeaseCost
9623
us-gaap Lease Cost
LeaseCost
36197
us-gaap Lease Cost
LeaseCost
99660
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
80924
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
111429
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
38203
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
69849
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
21703
CY2021Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
42482
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2022Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2021Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2022Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.118
CY2021Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.095
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2547
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3997
us-gaap Operating Lease Payments
OperatingLeasePayments
34791
us-gaap Operating Lease Payments
OperatingLeasePayments
147187
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
20779
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
23098
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
128473
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
11861
CY2022Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
6279
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
27675
CY2022Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
13149
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
4383
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
39536
CY2022Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
23811
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1333
CY2022Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
2108
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
38203
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
21703
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6812794
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1367874
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1198384
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6334717
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3482772

Files In Submission

Name View Source Status
0001558370-22-013086-index-headers.html Edgar Link pending
0001558370-22-013086-index.html Edgar Link pending
0001558370-22-013086.txt Edgar Link pending
0001558370-22-013086-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
otlk-20220630.xsd Edgar Link pending
otlk-20220630x10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
otlk-20220630xex31d1.htm Edgar Link pending
otlk-20220630xex31d2.htm Edgar Link pending
otlk-20220630xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
otlk-20220630_def.xml Edgar Link unprocessable
otlk-20220630_pre.xml Edgar Link unprocessable
otlk-20220630_lab.xml Edgar Link unprocessable
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
otlk-20220630_cal.xml Edgar Link unprocessable
otlk-20220630x10q_htm.xml Edgar Link completed